中文标题:帕博利珠单抗(Pembro)联合同步放化疗(cCRT)治疗不可切除的局部晚期非小细胞肺癌(NSCLC):KEYNOTE-799研究的最终分析 讲者:Martin Reck(德国,Grosshansdorf) 研究背景 在KEYNOTE-799研究中,针对未经治疗的不可切除的局部晚期Ⅲ期...
Purpose/Objective(s) In ENGOT-cx11/GOG-3047/KEYNOTE-A18 (NCT04221945), pembro + CCRT improved PFS (HR = 0.70 [95% CI = 0.550.89]; P = 0.0020) and showed a favorable trend in OS (HR = 0.73 [95% CI = 0.491.07]) vs placebo (pbo) + CCRT in high-risk LACC at interim ...
15.a. b. Jabbour SK, Lee KH, Frost N, et al. Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799. J Clin Oncol. 2020;38(15_suppl):9008. 16.a. b. Jabbour S...
15.a. b. Jabbour SK, Lee KH, Frost N, et al. Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799. J Clin Oncol. 2020;38(15_suppl):9008. 16.a. b. Jabbour S...
Schroeder on the Evolving Ovarian Cancer Treatment Landscape KEYNOTE-A18 Eligibility: Pembro/Chemoradiotherapy in Cervical Cancer Westin Discusses Insights From the DUO-E Trial in Endometrial Cancer Monk on KEYNOTE-A18 Data of Pembro/Chemoradiotherapy in Cervical CancerRelated...
15.a. b. Jabbour SK, Lee KH, Frost N, et al. Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799. J Clin Oncol. 2020;38(15_suppl):9008. ...
15.a. b. Jabbour SK, Lee KH, Frost N, et al. Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799. J Clin Oncol. 2020;38(15_suppl):9008. ...
8508 Background: Primary analysis (database cutoff, Oct 28, 2020) of the global KEYNOTE-799 study (NCT03631784) in patients (pts) with unresectable, locally advanced stage III NSCLC, showed that pembrolizumab (pembro; anti–PD-1) plus cCRT resulted in an ORR of 70.5% in cohort A (n =...